Moderna (NASDAQ:MRNA) Shares Down 6.8% – Time to Sell?

Moderna, Inc. (NASDAQ:MRNA) shares traded down 6.8% on Tuesday. The company traded as low as $250.49 and last traded at $250.83. 11,102,965 shares were traded during trading, a decline of 12% from the average session volume of 12,638,438 shares. The stock had previously closed at $269.00.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year, and raised its full-year 2026 revenue-growth forecast to 15%–25%. Lower costs and gains from respiratory vaccines also supported the improved outlook. Why is Moderna (MRNA) stock soaring today
• Positive Sentiment: Investors are also watching intismeran, Moderna’s personalized cancer therapy. Phase 3 data showed a 42% reduction in melanoma recurrence or death; the company is targeting an FDA filing by year-end 2026, with a possible decision in 2027. Moderna: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Moderna will present at the Jefferies Global Health Care Conference on November 18. The event may provide an update, but the announcement itself does not change the company’s outlook. Moderna to Present at Upcoming Conference in November 2026
• Negative Sentiment: Valuation is a key risk after the stock’s sharp run-up. Goldman Sachs raised its target to $195 but kept a neutral rating, while commentary argues that much of the expected sales growth may already be priced in. Goldman Sachs price-target update Moderna’s Q3 Numbers May Have Seemed Impressive, but They Aren’t Enough to Make the Stock a Buy
• Negative Sentiment: Despite the improved quarter, nearly all of Moderna’s revenue still comes from COVID-related products, leaving the company reliant on diversifying successfully into oncology and other areas. Moderna’s Q3 Numbers May Have Seemed Impressive, but They Aren’t Enough to Make the Stock a Buy

Analyst Upgrades and Downgrades

MRNA has been the subject of several recent analyst reports. Barclays upped their target price on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, August 24th. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research report on Tuesday, September 22nd. TD Cowen reiterated a “buy” rating on shares of Moderna in a research report on Wednesday, October 21st. Berenberg Bank increased their price target on Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a report on Friday, September 11th. Finally, Citigroup reissued a “sell” rating on shares of Moderna in a research report on Friday, October 23rd. Six equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $113.75.

Moderna Price Performance

The business’s 50-day moving average price is $194.47 and its 200 day moving average price is $92.61. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The stock has a market capitalization of $100.14 billion, a PE ratio of -35.33 and a beta of 1.16.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company’s revenue for the quarter was up 29.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.51) EPS. Research analysts forecast that Moderna, Inc. will post -6.11 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,145 shares of Moderna stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock worth $33,875,904 over the last three months. Company insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MRNA. Voya Investment Management LLC grew its position in Moderna by 6.4% in the 3rd quarter. Voya Investment Management LLC now owns 381,195 shares of the company’s stock worth $73,407,000 after purchasing an additional 22,843 shares during the period. Public Sector Pension Investment Board boosted its stake in shares of Moderna by 57.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 159,311 shares of the company’s stock worth $30,679,000 after buying an additional 58,448 shares during the last quarter. Garrison Point Advisors LLC purchased a new position in shares of Moderna in the 3rd quarter worth $453,000. Cibc World Market Inc. grew its holdings in shares of Moderna by 50.7% in the third quarter. Cibc World Market Inc. now owns 25,307 shares of the company’s stock worth $4,873,000 after acquiring an additional 8,510 shares during the period. Finally, Edgestream Partners L.P. bought a new stake in shares of Moderna in the third quarter worth $2,111,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.